Group 1 - Company announced a placement agreement with an exclusive placement agent to issue 105 million shares at a price of HKD 29.62 per share, which represents a discount of 6.50% compared to the closing price of HKD 31.68 on the trading day prior to the agreement [1] - The placement shares will account for approximately 4.14% of the total issued shares after the placement, assuming no changes in the company's issued share capital from the announcement date until completion [1] Group 2 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion after deducting placement commissions and other related expenses [2] - Approximately 80% of the net proceeds will be used for research and development, including advancing clinical studies for innovative drugs in China and the US, and supporting the expansion of indications for commercialized drugs [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]
三生制药拟折让6.50%配股 净筹约30.87亿港元